Prosecution Insights
Last updated: April 19, 2026

Examiner: VAJDA, KRISTIN ANN

Tech Center 1600 • Art Units: 1622 1626

This examiner grants 84% of resolved cases

Performance Statistics

84.2%
Allow Rate
+24.2% vs TC avg
1617
Total Applications
+10.5%
Interview Lift
751
Avg Prosecution Days
Based on 1581 resolved cases, 2023–2026

Rejection Statute Breakdown

1.1%
§101 Eligibility
27.6%
§102 Novelty
11.2%
§103 Obviousness
33.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18557276 METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR Non-Final OA LG CHEM, LTD.
18263772 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS Non-Final OA LG CHEM, LTD.
17636003 MITOCHONDRIAL MODULATION TO IMPROVE METABOLIC SYNDROME DURING AGING Non-Final OA Shanghai Jiao Tong University
18263582 ENZYME INHIBITORS AND VIRAL INFECTION THERAPY Non-Final OA UNIVERSITY OF SOUTHERN CALIFORNIA
18572042 CHOLINATE OF 2-(1-CYCLOBUTYL-1H-PYRAZOL-4-YL)-5-[([{1-[2-FLUORO-4-(TRIFLUOROMETHYL)-PHENYL]CYCLOPROPYL}CARBONYL)AMINO]BENZOIC ACID Non-Final OA Bayer Aktiengesellschaft
17774571 BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS Final Rejection Board of Trustees of Michigan State University
18759253 CDK2 DEGRADERS AND USES THEREOF Non-Final OA Kymera Therapeutics, Inc.
18009005 METHOD FOR STARTING UP A REACTOR FOR PREPARING PHTHALIC ANHYDRIDE Non-Final OA Clariant International Ltd
17785184 UNNATURAL AMINO ACIDS AND USES THEREOF Final Rejection Temple University-Of The Commonwealth System of Higher Education
18576412 POLYMORPHS OF PONESIMOD Non-Final OA TEVA CZECH INDUSTRIES S.R.O
18561624 NOVEL CINNAMAMIDE DERIVATIVES AND USE THEREOF Non-Final OA KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
18561712 TREATMENT OF ANTIPHOSPHOLIPID SYNDROME USING S-HYDROXYCHLOROQUINE Non-Final OA Genovate Biotechnology Co. Ltd.
18561634 OPHTHALMIC PREPARATION FOR MYOPIA SUPPRESSION Non-Final OA TSUBOTA LABORATORY, INC.
18009206 QUINOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Final Rejection IDEAYA BIOSCIENCES, INC.
18490704 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE Non-Final OA Arvinas Operations, Inc.
18287612 sGC STIMULATORS Non-Final OA Tisento Therapeutics Inc.
18490418 TUNING SULFONATION AND CONTROLLING OLEO-FURAN SURFACTANT COMPOSITIONS Non-Final OA SIRONIX RENEWABLES, INC.
18553392 COMPOSITION FOR PREVENTING OR TREATING CHRONIC KIDNEY DISEASE, COMPRISING COMPOUND THAT INDUCES EXPRESSION OF ANTI-AGING GENE KLOTHO Non-Final OA KLOTHO SCIENCES
18549124 COMPOSITION OF THE PHYTOCOMPOUNDS INTENDED TO ENHANCE CYTOTOXIC ACTIVITY IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA Non-Final OA FUNDACJA GETRESPONSE CARES
18457560 EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF Non-Final OA Miracure Biotechnology Limited
18262777 PROCESS FOR MANUFACTURING A DIPHENYLPHRAZINE DERIVATIVE Non-Final OA ACTELION PHARMACEUTICALS LTD
18275880 ARYLTHIOETHER ACETAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Non-Final OA X-Biotix Therapeutics, Inc.
18267313 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER Non-Final OA LT MATERIALS CO., LTD.
17759490 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY Final Rejection EVOTEC INTERNATIONAL GMBH
18015040 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION Final Rejection KLOTHO THERAPEUTICS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month